Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 17/20 | 0.64 |
| ▸ | PDE4D | Q08499 | 5/20 | 0.54 |
| ▸ | PDE4A | P27815 | 3/20 | 0.54 |
| ▸ | PDE4C | Q08493 | 3/20 | 0.54 |
| ▸ | CTSB | P07858 | 1/20 | 0.53 |
| ▸ | CTSS | P25774 | 1/20 | 0.53 |
| ▸ | CTSK | P43235 | 1/20 | 0.53 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.51 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL682541 | 0.87 | ALK (0.49) | PDE4BPDE4DPDE4APDE4CALK | |
| SCHEMBL681899 | 0.82 | PDE4B (0.53) | PDE4BPDE4DPDE4APDE4CCTSB | |
| SCHEMBL682979 | 0.82 | PDE4B (0.53) | PDE4BPDE4DPDE4APDE4CCTSB | |
| SCHEMBL16476067 | 0.82 | PDE4B (0.50) | PDE4BPDE4DPDE4APDE4C | |
| SCHEMBL882288 | 0.81 | TACR3 (0.48) | PDE4BPDE4DPDE4APDE4CCTSB | |
| SCHEMBL18744666 | 0.81 | PDE4B (0.51) | PDE4BPDE4DPDE4APDE4CCTSB | |
| SCHEMBL683235 | 0.79 | PDE4B (0.56) | PDE4BPDE4DPDE4APDE4C | |
| SCHEMBL6539208 | 0.79 | GFER (0.57) | — | |
| SCHEMBL1911851 | 0.79 | TGFBR1 (0.54) | ALK | |
| SCHEMBL19002643 | 0.79 | GFER (0.53) | ALK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8927546-B2 | Therapeutic piperazines | DART NEUROSCIENCE (CAYMAN) LTD. (KY) | 2015-01-06 | — | — | US | disclosed |
| US-20110065691-A1 | THERAPEUTIC PIPERAZINES | DART NEUROSCIENCE (CAYMAN) LTD. (KY) | 2011-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110065691-A1 | THERAPEUTIC PIPERAZINES | PDE4A, PDE4B, PDE4D | PDE4B 2/4885PDE4D 3/4885PDE4A 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.